C

Cytosorbents Corp
D

CTSO

1.15000
USD
0.03
(2.68%)
مغلق
حجم التداول
1,180
الربح لكل سهم
-0
العائد الربحي
-
P/E
-3
حجم السوق
70,069,004
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    BDX
    BDX
    -0.590
    (-0.26%)
    227.450 USD
    B
    BIO
    -6.57
    (-2.29%)
    279.85 USD
    G
    GH
    -4.510
    (-9.51%)
    42.910 USD
    H
    HOLX
    0.180
    (0.28%)
    64.510 USD
    ISRG
    ISRG
    -15.37
    (-2.53%)
    591.50 USD
    TMO
    TMO
    -5.71
    (-1.06%)
    532.28 USD
    T
    TRIB
    -0.01690
    (-2.19%)
    0.75500 USD
    V
    VCYT
    -1.820
    (-4.43%)
    39.230 USD
    المزيد
الأخبار
المقالات

العنوان: Cytosorbents Corp

القطاع: Healthcare
الصناعة: Medical Devices
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.